Vectura Group has appointed Will Downie as chief executive officer and executive director of the company with effect from November 7, 2019. 
 
Prior to joining Vectura, Mr. Downie spent ten years as the senior vice president, global sales and marketing at Catalent, one of the world’s largest contract development and manufacturing organizations (CDMO).
 
In his role at Catalent, he led the commercial effort and had responsibility for global sales, marketing and commercial operations activities. During his tenure, he helped drive the long-term growth of the company as well as positioning Catalent as one of the leading brands in the pharmaceutical services space. He has a deep understanding of the development and advanced drug delivery market and has amassed significant experience in driving sustained long-term results, as well as building performance-focused organizations and meeting customer needs on a global scale.
 
“I am very pleased to welcome Will Downie as Vectura’s new CEO,” said Bruno Angelici, chairman, Vectura. “He brings a wealth of relevant experience which will help Vectura to grow and deliver on its new strategic focus as a leading inhaled CDMO business.
 
“I would like to thank Paul Fry for the significant work he has done since stepping into the interim chief executive role and driving the change necessary for Vectura to become a leading player in the inhaled CDMO space. Paul will resume his responsibilities as chief financial officer from November 7, 2019.”